This Lifesciences Company Secures USFDA Approval for Eluxadoline Tablets with 180-Day Exclusivity; Stock Price Logged 135.25 per cent Returns in 3 years This Lifesciences Company Secures USFDA Approval for Eluxadoline Tablets with 180-Day Exclusivity; Stock Price Logged 135.25 per cent Returns in 3 years With a PE ratio of 20x, the company trades at a discount compared to the industry PE of 28x. The company has ROCE of 22.3 per cent and ROE of 20.7 per cent. DSIJ Intelligence / Monday, March 17, 2025 0 143 Article rating: 5.0 Read more
Zydus group Company Invests in Illexcor for Sickle Cell Treatment; Stock Gave 139.65 per cent in last 3 Years Zydus group Company Invests in Illexcor for Sickle Cell Treatment; Stock Gave 139.65 per cent in last 3 Years Over the past three years, the stock has delivered a substantial return of 139.65 per cent, classifying it as a multibagger stock. DSIJ Intelligence / Thursday, March 13, 2025 0 126 Article rating: 5.0 Read more
New Drug Launch: Transforming Cardiometabolic Care in India New Drug Launch: Transforming Cardiometabolic Care in India Glenmark Pharmaceuticals Ltd, a prominent global pharmaceutical company, has expanded its cardiometabolic portfolio by launching Empagliflozin and its fixed-drug combinations in India. DSIJ Intelligence / Wednesday, March 12, 2025 0 214 Article rating: 5.0 The company continues to strengthen its presence in the cardiometabolic care segment, addressing the rising prevalence of diabetes and cardiovascular diseases in India. Read more
Pharma Stock Soars 4 per cent Following FDA Approval and Strategic Partnership with Leading US Company Pharma Stock Soars 4 per cent Following FDA Approval and Strategic Partnership with Leading US Company FDA Nod for Key Diabetes Treatment Boosts Market Confidence and Stock Performance DSIJ Intelligence / Tuesday, January 7, 2025 0 321 Article rating: 5.0 FDA Nod for Key Diabetes Treatment Boosts Market Confidence and Stock Performance Read more
This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA. This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA. The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years. DSIJ Intelligence / Friday, August 9, 2024 0 335 Article rating: 3.7 The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years. Read more